Bristol-Myers Squibb invested $3.7 billion in 2013
to discover and develop innovative medicines to help patients
prevail against serious diseases.
In the past several years, we have delivered a number of new
products for patients in need, including medicines for
rheumatoid arthritis, hepatitis B, cancer, HIV/AIDS and
diabetes. As we look to the future, our
continues to expand as we have approximately 55
compounds in development, of which, nearly half are biologics.
Below is a list of the disease areas in which we focus:
- Fibrotic Diseases
- Exploratory Areas
In the true spirit of science, we
are dedicated sharing our clinical trials information and data with
patients, medical/research communities, the media, policy makers and the
general public, consistent with the
Principles for Responsible Clinical Trial Data Sharing (Principles)
released by the U.S. and European pharmaceutical trade associations, PhRMA
and EFPIA, which support the safeguarding of patient privacy and informed
consent, respecting the integrity of national regulatory systems and
maintaining incentives for investment in biomedical research.
We act on our belief that the priceless ingredient of every product
is the integrity of its maker.